Share Twitter LinkedIn Facebook Email Michael N. Needle, MD, and Chief Medical Officer of AVEO Oncology goes over the TIVO-1 Trial results first released in 2014. On August 28, 2017 it was announces that Tivozanib (FOTIVDA®) has been approved in the EU for RCC patients.
Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD Acute Lymphoblastic Leukemia 4 Mins Read
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read